The biodefense market is estimated to be valued at US$ 13.4 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

The biodefense market consists of countermeasures such as vaccines, drugs, and diagnostic tools used to detect and treat diseases caused by biological weapons or bioterrorism agents. Some key products in this market include anthrax vaccines, smallpox vaccines, radiological/nuclear countermeasures, and broad-spectrum antibiotics. With rising threats from biological weapons, there is a growing need for biodefense solutions to protect against bioterrorism and warfare.

Market Dynamics:

One of the key drivers for growth of the biodefense market is the growing threat of biological weapons and acts of bioterrorism across the globe. Various terrorist groups and rogue states are known to possess or are developing biological weapons. This poses serious security threats and has increased investments by governments towards biodefense preparedness. Additionally, the frequent outbreaks of infectious diseases are also fueling demand for biodefense products. For instance, the ongoing COVID-19 pandemic has highlighted the need for universal access to medical countermeasures. Further, increasing R&D activities focused on developing next-generation biodefense therapies and the presence of favorable government funding & regulatory policies are also expected to boost the market growth over the forecast period.

The Global Biodefense Market Size is expected to witness high growth, exhibiting CAGR of 4.8% over the forecast period, due to increasing threats of biological weapons and emerging infectious diseases. Government initiatives to strengthen preparedness against bioterrorism are driving investments in new diagnostic tools, vaccines, and therapies.

Read More

https://healthcarelatesteditionnews.blogspot.com/2023/11/biodefense-is-estimated-to-witness-high.html